LIQUID BIOPSY MARKET ANALYSIS

Liquid Biopsy Market – Insights

Liquid biopsy is an advanced cancer diagnostic test that uses bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine for detecting cancer. This non-invasive diagnostic test uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers for diagnosis of cancer.

The global liquid biopsy market is estimated to account for US$ 3,535.1 Mn in terms of value by the end of 2027.

Global Liquid Biopsy Market: Drivers

Increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, increasing funding for R&D in cancer is also expected to aid in growth of the market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.

North America region held dominant position in the global liquid biopsy market in 2019, accounting for 50.7% share in terms of value, followed by Europe.

Figure 1. Global Liquid Biopsy Market Value (US$ Mn), by Region, 2019

To learn more about this report, request a free sample copy

Global Liquid Biopsy Market: Restraints

Levels of circulating free DNA (cfDNA) in serum and plasma vary. Such changes in cfDNA levels among patients may lead to inaccurate or unreliable test results in liquid biopsy, thereby hindering growth of the global liquid biopsy market.

Moreover, high cost of liquid biopsy is also expected to hinder growth of the market. Various expenses associated with liquid biopsy include cost of equipment & reagents and labor & professional costs.

Global Liquid Biopsy Market: Opportunities

Microfluidics is characterized by the precise manipulation of fluid within sub-millimeter channels. Many researches are ongoing for the development of lab-on-a-chip devices for biochemical analyses such as cell separation, DNA and protein analyses, and PCR amplification.

Moreover, adoption of cfDNA to monitor tumor alterations and tumor progression is expected to offer lucrative growth opportunities for players in the market.

To learn more about this report, request a free sample copy

ctNA (Circulating Tumor Nucliec Acids) segment in the global liquid biopsy market was valued at US$ 250.0 Mn in 2019 and is expected to reach US$ 1,723.6 Mn by 2027 at a CAGR of 27.3% during the forecast period.

Market Trends/Key Takeaways

The use of breast milk in diagnosis of breast cancer is being tested. For instance, in February 2020, Dr. Katrina Mitchell, MD, a fellowship-trained breast surgeon of IBCLC, FACS, partnered with University of Massachusetts-Amherst cancer researchers to assess use of breast milk from nursing women for determining pathogenic BRCA1 or BRCA2 genetic mutation.

Players in the market are focused on partnering with various institutes for R&D in liquid biopsy. For instance, in February 2020, Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. collaborated with National Cancer Center (NCC) for the use of FoundationOneLiquid, Foundation Medicine’s laboratory-developed liquid biopsy test, in the third stage of SCRUM-Japan, a cancer genomic screening consortium in Japan.

Global Liquid Biopsy Market: Competitive Landscape

Major players operating in the global liquid biopsy market include, Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.

Global Liquid Biopsy Market: Key Developments

Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Saga Diagnostics signed agreements with Laboratoires Servier to perform liquid biopsy testing on cancer patients enrolled in clinical studies.

Major players in the market are also focused on presenting their products at major symposiums. For instance, in January 2020, GRAIL, Inc. presented new data from its trial, CCGA, for liquid biopsy at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which failed to show marked improvement in sensitivity compared with data presented at the symposium in 2019.